Update on glucocorticoid-induced osteoporosis

Rheumatic Disease Clinics of North America

Volumn 37, Issue 3, 2011, Pages 415-431

  Maricic, Michael ^a,b  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^b Catalina Pointe Rheumatology   (United States)

Author keywords

Bisphosphonates; Fractures; Glucocorticoids; Osteoblasts; Osteoporosis; Teriparatide

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL; BETA CATENIN; BETA INTERFERON; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CALCIUM CARBONATE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ERGOCALCIFEROL; ETIDRONIC ACID; GLUCOCORTICOID; IBANDRONIC ACID; INTERLEUKIN 6; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PAMIDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; PREDNISOLONE; PREDNISONE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VITAMIN D; WNT PROTEIN; ZOLEDRONIC ACID;

BONE DENSITY; CELL SURVIVAL; CORTICOSTEROID INDUCED OSTEOPOROSIS; CYTOKINE RELEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRACTURE; HUMAN; LOW DRUG DOSE; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOCYTE; OSTEOLYSIS; PATHOGENESIS; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE;

ARTHRITIS, RHEUMATOID; BONE DENSITY CONSERVATION AGENTS; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RISK FACTORS;

EID: 82455192776     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2011.07.003     Document Type: Review

References (64)

1. Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary basophilism). Bull Johns Hopkins Hosp 1932, 50:137-195.
2. Hench P.H., Kendall P., Slocumb C.H., et al. The effect of a hormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Mayo Clin Proc 1949, 24(8):181-197.
3. Curtis P.H., Clark W.S., Herndon C.H. Vertebral fractures resulting from prolonged cortisone and corticotropin therapy. JAMA 1954, 156:467-469.
4. Saag K.G., Koehnke R., Caldwell J.R., et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. Am J Med 1994, 96(2):115-123.
5. van Staa T.P., Cooper C., Abenhaim L., et al. Utilization of oral corticosteroids in the United Kingdom. Q J Med 2000, 93:105-111.
6. Dempster D.W. Bone histomorphometry in glucocorticoid-induced osteoporosis. J Bone Miner Res 1989, 4:137-141.
7. Carbonare L.D., Bertoldo F., Valenti M.T., et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005, 36:645-652.
8. Weitzmann M.N., Pacifici R. Estrogen deficiency and bone loss: an inflammatory tale. J Clin Invest 2006, 116:1186-1194.
9. Hofbauer L.C., Gori F., Riggs B.L., et al. Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis. Endocrinology 1999, 140:4382-4389.
10. Alesci S., De Martino M.U., Illias I. Glucocorticoid-induced osteoporosis: from basic mechanisms to clinical aspects. Neuroimmunomodulation 2005, 12:1-19.
11. Dovio A., Perazzolo L., Saba L., et al. High-dose glucocorticoids increase serum levels of soluble Il-6 receptor alpha and its ratio to soluble gp130: an additional mechanism for early increased bone resorption. Eur J Endocrinol 2006, 154:745-751.
12. Takuma A., Kaneda T., Sato T., et al. Dexamethasone enhances osteoclasts formation synergistically with transforming growth factor-beta by stimulating the priming of osteoclast progenitors for differentiation into osteoclasts. J Biol Chem 2003, 278:44667-44674.
13. Jia D., O'Brien C.A., Stewart S.A., et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006, 147:5592-5599.
14. Weinstein R.S., Jilka R.L., Parfitt A.M., et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274-282. 25.
15. Canalis E. Glucocorticoid-induced osteoporosis: pathophysiology. Bone disease in rheumatology 2005, 105-110. Lippincott, New York. M. Maricic, O. Gluck (Eds.).
16. Pereira R.C., Delany A.M., Canalis E. Effects of cortisol and bone morphogenetic protein-2 on stromal cell differentiation: correlation with CCAAT-enhancer binding protein expression. Bone 2002, 30:685-691.
17. Ohnaka K., Tanabe M., Kawate H., et al. Glucocorticoid suppresses the canonical Wnt signal in human osteoblast. Biochem Biophys Res Commun 2005, 329:177-181.
18. Leclerc N., Lupen C.A., Ho V.V. Gene expression profiling of glucocorticoid-inhibited osteoblasts. J Mol Endocrinol 2004, 33(1):175-193.
19. Delany A.M., Jeffrey J.J., Rydziel S., et al. Cortisol increases interstitial collagenase expression in osteoblasts by post-transcriptional mechanisms. J Biol Chem 1995, 270:26607-26612.
20. Delany A.M., Durant D., Canalis E. Glucocorticoid suppression of IGF I transcription in osteoblasts. Mol Endocrinol 2001, 15:1781-1789.
21. Weinstein R.S., Powers C.C., Parfitt A.M., et al. Preservation of osteocyte viability by bisphosphonates contributes to bone strength in glucocorticoid-treated mice independently of BMD: an unappreciated determinant of bone strength. J Bone Miner Res 2002, 17(Suppl 1):S156.
22. Laan R.F., van Riel P.L., van de Putte L.B., et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993, 119(10):963-968.
23. Steinbuch M., Thomas E., Youket E., et al. Oral glucocorticoid use is associated with an increased risk of fracture. Osteoporos Int 2004, 15:323-328.
24. Kanis J.A., Johannson H., Oden A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 2004, 19:893-899.
25. van Staa T., Leufkens H., Abenhaim L., et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000, 15(6):993-1000.
26. van Staa T.P., Leufkens H.M., Abenhaim L., et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000, 39:1383-1389.
27. Hubbard R.B., Smith C.J., Smeeth L., et al. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med 2002, 166:1563-1566.
28. van Staa T.P., Leufkens H.G., Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001, 3:581-588.
29. Angeli A., Gugliemi G., Dovio A., et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy; a cross-sectional outpatient study. Bone 2006, 39:253-259.
30. World Health Organization Assessment of fracture risk and its application to screening for postmenopausal osteoporosis 1994, Technical report series 843, WHO, Geneva (Switzerland).
31. Van Staa T.P., Laan R.F., Barton I.P., et al. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum 2003, 48(11):3224-3229.
32. Cohen S., Levy R.M., Keller M., et al. Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum 1999, 42(11):2309-2318.
33. Reid D.M., Hughes R., Laan R.F. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. J Bone Miner Res 2000, 15:1006-1013.
34. Grossman J.M., Gordon R., Ranganath V.K., et al. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010, 62:1515-1526.
35. Buckley L.M., Leib E.S., Cartularo K.S., et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996, 125:961-968.
36. Amin S., LaValley M.P., Simms R.W., et al. The role of vitamin D in corticosteroid-induced osteoporosis: a meta-analytic approach. Arthritis Rheum 1999, 42:1740-1751.
37. de Nijs R.N., Jacobs J.W., Algra A., et al. Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies. Osteoporos Int 2004, 15:589-602.
38. Saag K.G., Emkey R., Schnitzer T., et al. Alendronate for the treatment and prevention glucocorticoid-induced osteoporosis. N Engl J Med 1998, 339:292-299.
39. Adachi J.D., Saag K., Emkey R., et al. Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids. Arthritis Rheum 2001, 44:202-211.
40. Wallach S., Cohen S., Reid D.M., et al. Effects of risedronate treatment on bone density an vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000, 67:277-285.
41. Adachi J.D., Bensen W.G., Brown J., et al. Intermittent etidronate therapy to prevent corticosteroid induced osteoporosis. N Engl J Med 1997, 337:382-387.
42. Amin S., LaValley M.P., Simms R.W., et al. The comparative efficacy of drug therapies used for the management of corticosteroid-induced osteoporosis: a meta-regression. J Bone Miner Res 2002, 17:1512-1526.
43. Boutsen Y., Jamart J., Esselinckx W., et al. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone. J Bone Miner Res 2001, 16(1):104-112.
44. Ringe J.D., Dorst A., Faber H., et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos Int 2003, 14(10):801-807.
45. Green J.R., Rogers M.J. Pharmacological profile of zoledronic acid: a highly potent inhibitor of bone resorption. Drug Dev Res 2002, 55:210-224.
46. Reid D.M., Devogelaer J.P., Saag K., et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy randomised controlled trial. Lancet 2009, 373:1253-1263.
47. Canalis E., Giustina A., Bilizekian J.P. Mechanisms of anabolic therapies for osteoporosis. N Engl J Med 2007, 357:905-916.
48. Lane N.E., Sanchez S., Modin G.W., et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest 1998, 102(8):1627-1633.
49. Lane N.E., Sanchez S., Modin G.W., et al. Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid induced osteoporosis: results of a randomized controlled clinical trial. J Bone Miner Res 2000, 15(5):944-951.
50. Saag K.G., Shane E.S., Boonen S., et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007, 357:2028-2039.
51. Langdahl B.L., Marin F., Shane E., et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: analysis by gender and menopausal status. Osteoporos Int 2009, 20:2095-2103.
52. Saag K.G., Zancetta J.R., Devogelear J.P., et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty six-month results of a randomized, double-blind controlled trial. Arthritis Rheum 2009, 60:3346-3355.
53. Healey J.H., Paget S.A., Williams-Russo P., et al. A randomized controlled trial of salmon calcitonin to prevent bone loss in corticosteroid-treated temporal arteritis and polymyalgia rheumatica. Calcif Tissue Int 1996, 58:73-80.
54. Hall G.M., Daniels M., Doyle D.V., et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994, 37:1499-1505.
55. Reid I.R., Wattie D.J., Evans M.C., et al. Testosterone therapy in glucocorticoid-treated men. Arch Intern Med 1996, 156:1173-1177.
56. Rossouw J.W., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy post-menopausal women: principal results from the women's health initiative randomized controlled trial. JAMA 2002, 288:321-333.
57. Rhoden E.L., Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004, 350:482-492.
58. Kanis J.A., Johnell O., Oden A., et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 18:1033-1046.
59. Kanis J.A., Johansson H., Oden A., et al. Guidance for adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011, 22:809-816.
60. Curtis J.R., Westfall A.O., Allison J.J., et al. Longitudinal patterns in the prevention of osteoporosis in Glucocorticoid-treated patients. Arthritis Rheum 2005, 52:2485-2494.
61. Guzman-Clark J.R., Fang M.A., Fehl M.E., et al. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 2007, 57:140-146.
62. Solomon D.H., Katz J.N., Jacobs J.P., et al. Management of glucocorticoid-induced osteoporosis in patients with rheumatoid arthritis: rates and predictors of care in an academic rheumatology practice. Arthritis Rheum 2002, 46:3136-3142.
63. Newman E.D., Matsko C.K., Oleginski T.P., et al. Glucocorticoid-induced osteoporosis program (GIOP): a normal, comprehensive and successful program with improved outcomes at one year. Osteoporos Int 2006, 17:1428-1434.
64. Beukelman T., Saag K.G., Curtis J.R. Cost-effectiveness of multifaceted implementation programs for the prevention of glucocorticoid-induced osteoporosis. Osteoporos Int 2010, 21:1573-1584.